# Manuel A F V GonÃ§alves

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6276873/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 55<br>papers | 2,506<br>citations | 201385<br>27<br>h-index | 205818<br>48<br>g-index |
| 55<br>all docs | 55<br>docs citations | 55<br>times ranked | 3033<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Large-scale genome editing based on high-capacity adenovectors andÂCRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells. Nucleic Acids Research, 2022, 50, 7761-7782. | 6.5 | 9 |
| 2 | A primer to gene therapy: Progress, prospects, and problems. Journal of Inherited Metabolic Disease, 2021, 44, 54-71. | 1.7 | 9 |
| 3 | Broadening the reach and investigating the potential of prime editors through fully viral gene-deleted adenoviral vector delivery. Nucleic Acids Research, 2021, 49, 11986-12001. | 6.5 | 19 |
| 4 | Precise and broad scope genome editing based on high-specificity Cas9 nickases. Nucleic Acids Research, 2021, 49, 1173-1198. | 6.5 | 29 |
| 5 | TGF-Î²-Induced Endothelial to Mesenchymal Transition Is Determined by a Balance Between SNAIL and ID Factors. Frontiers in Cell and Developmental Biology, 2021, 9, 616610. | 1.8 | 18 |
| 6 | Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components. Gene Therapy, 2020, 27, 209-225. | 2.3 | 42 |
| 7 | Expanding the editable genome and CRISPRâ€“Cas9 versatility using DNA cutting-free gene targeting based on in trans paired nicking. Nucleic Acids Research, 2020, 48, 974-995. | 6.5 | 25 |
| 8 | Novel Therapeutic Approaches for the Treatment of Retinal Degenerative Diseases: Focus on CRISPR/Cas-Based Gene Editing. Frontiers in Neuroscience, 2020, 14, 838. | 1.4 | 12 |
| 9 | Adenoviral Vectors Meet Gene Editing: A Rising Partnership for the Genomic Engineering of Human Stem Cells and Their Progeny. Cells, 2020, 9, 953. | 1.8 | 19 |
| 10 | High-Capacity Adenoviral Vectors Permit Robust and Versatile Testing of DMD Gene Repair Tools and Strategies in Human Cells. Cells, 2020, 9, 869. | 1.8 | 19 |
| 11 | Genomic Engineering in Human Hematopoietic Stem Cells: Hype or Hope?. Frontiers in Genome Editing, 2020, 2, 615619. | 2.7 | 5 |
| 12 | A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies. Frontiers in Genome Editing, 2020, 2, 617780. | 2.7 | 7 |
| 13 | Precise and non-disruptive gene editing based on programmable nickases. Cell & Gene Therapy Insights, 2020, 6, 427-435. | 0.1 | 0 |
| 14 | Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing. Journal of Medical Genetics, 2019, 56, 828-837. | 1.5 | 27 |
| 15 | The Chromatin Structure of CRISPR-Cas9 Target DNA Controls the Balance between Mutagenic and Homology-Directed Gene-Editing Events. Molecular Therapy - Nucleic Acids, 2019, 16, 141-154. | 2.3 | 39 |
| 16 | DNA, RNA, and Protein Tools for Editing the Genetic Information in Human Cells. IScience, 2018, 6, 247-263. | 1.9 | 25 |
| 17 | Correction of Recessive DystrophicÂEpidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes. Journal of Investigative Dermatology, 2017, 137, 836-844. | 0.3 | 24 |
| 18 | The Chromatin Structure Differentially Impacts High-Specificity CRISPR-Cas9 Nuclease Strategies. Molecular Therapy - Nucleic Acids, 2017, 8, 558-563. | 2.3 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | In trans paired nicking triggers seamless genome editing without double-stranded DNA cutting. Nature Communications, 2017, 8, 657. | 5.8 | 74 |
| 20 | The emerging role of viral vectors as vehicles for DMD gene editing. Genome Medicine, 2016, 8, 59. | 3.6 | 18 |
| 21 | Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells. Scientific Reports, 2016, 6, 37051. | 1.6 | 60 |
| 22 | Probing the impact of chromatin conformation on genome editing tools. Nucleic Acids Research, 2016, 44, 6482-6492. | 6.5 | 111 |
| 23 | Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations. Nucleic Acids Research, 2016, 44, 1449-1470. | 6.5 | 63 |
| 24 | Engineered Viruses as Genome Editing Devices. Molecular Therapy, 2016, 24, 447-457. | 3.7 | 119 |
| 25 | Genome editing at the crossroads of delivery, specificity, and fidelity. Trends in Biotechnology, 2015, 33, 280-291. | 4.9 | 121 |
| 26 | Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nature Methods, 2014, 11, 1051-1057. | 9.0 | 123 |
| 27 | Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells. Methods, 2014, 69, 179-187. | 1.9 | 32 |
| 28 | Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Scientific Reports, 2014, 4, 5105. | 1.6 | 121 |
| 29 | Lentiviral Vectors Encoding Zinc-Finger Nucleases Specific for the Model Target Locus HPRT1. Methods in Molecular Biology, 2014, 1114, 181-199. | 0.4 | 9 |
| 30 | Histone Deacetylase Inhibition Activates Transgene Expression from Integration-Defective Lentiviral Vectors in Dividing and Non-Dividing Cells. Human Gene Therapy, 2013, 24, 78-96. | 1.4 | 50 |
| 31 | Development of an AdEasyâ€based system to produce firstâ€and secondâ€generation adenoviral vectors with tropism for CARâ€or CD46â€positive cells. Journal of Gene Medicine, 2013, 15, 1-11. | 1.4 | 25 |
| 32 | Histone Deacetylase Inhibition Rescues Gene Knockout Levels Achieved with Integrase-Defective Lentiviral Vectors Encoding Zinc-Finger Nucleases. Human Gene Therapy Methods, 2013, 24, 399-411. | 2.1 | 19 |
| 33 | Targeted Gene Addition in Human Epithelial Stem Cells by Zinc-finger Nuclease-mediated Homologous Recombination. Molecular Therapy, 2013, 21, 1695-1704. | 3.7 | 53 |
| 34 | Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Research, 2013, 41, e63-e63. | 6.5 | 246 |
| 35 | Concerted nicking of donor and chromosomal acceptor DNA promotes homology-directed gene targeting in human cells. Nucleic Acids Research, 2012, 40, 3443-3455. | 6.5 | 17 |
| 36 | Nonspaced inverted DNA repeats are preferential targets for homology-directed gene repair in mammalian cells. Nucleic Acids Research, 2012, 40, 1984-1999. | 6.5 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Myogenic Properties of Human Mesenchymal Stem Cells Derived from Three Different Sources. Cell Transplantation, 2012, 21, 153-173. | 1.2 | 73 |
| 38 | Adenoviral Vectors Stimulate Glucagon Transcription in Human Mesenchymal Stem Cells Expressing Pancreatic Transcription Factors. PLoS ONE, 2012, 7, e48093. | 1.1 | 11 |
| 39 | Long-Term Contribution of Human Bone Marrow Mesenchymal Stromal Cells to Skeletal Muscle Regeneration in Mice. Cell Transplantation, 2011, 20, 217-232. | 1.2 | 53 |
| 40 | Transcription Factor Rational Design Improves Directed Differentiation of Human Mesenchymal Stem Cells Into Skeletal Myocytes. Molecular Therapy, 2011, 19, 1331-1341. | 3.7 | 29 |
| 41 | Rapid and Sensitive Lentivirus Vector-Based Conditional Gene Expression Assay to Monitor and Quantify Cell Fusion Activity. PLoS ONE, 2010, 5, e10954. | 1.1 | 10 |
| 42 | Stimulation of homology-directed gene targeting at an endogenous human locus by a nicking endonuclease. Nucleic Acids Research, 2009, 37, 5725-5736. | 6.5 | 36 |
| 43 | Genetic Complementation of Human Muscle Cells via Directed Stem Cell Fusion. Molecular Therapy, 2008, 16, 741-748. | 3.7 | 33 |
| 44 | Targeted Chromosomal Insertion of Large DNA into the Human Genome by a Fiber-Modified High-Capacity Adenovirus-Based Vector System. PLoS ONE, 2008, 3, e3084. | 1.1 | 19 |
| 45 | Modular and excisable molecular switch for the induction of gene expression by the yeast FLP recombinase. BioTechniques, 2006, 41, 711-713. | 0.8 | 6 |
| 46 | Adenovirus: from foe to friend. Reviews in Medical Virology, 2006, 16, 167-186. | 3.9 | 100 |
| 47 | Human mesenchymal stem cells ectopically expressing full-length dystrophin can complement Duchenne muscular dystrophy myotubes by cell fusion. Human Molecular Genetics, 2006, 15, 213-221. | 1.4 | 77 |
| 48 | Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells. Molecular Therapy, 2006, 13, 976-986. | 3.7 | 36 |
| 49 | Endowing Human Adenovirus Serotype 5 Vectors with Fiber Domains of Species B Greatly Enhances Gene Transfer into Human Mesenchymal Stem Cells. Stem Cells, 2005, 23, 1598-1607. | 1.4 | 54 |
| 50 | A concise peer into the background, initial thoughts and practices of human gene therapy. BioEssays, 2005, 27, 506-517. | 1.2 | 19 |
| 51 | Transfer of the Full-Length Dystrophin-Coding Sequence into Muscle Cells by a Dual High-Capacity Hybrid Viral Vector with Site-Specific Integration Ability. Journal of Virology, 2005, 79, 3146-3162. | 1.5 | 43 |
| 52 | Adeno-associated virus: from defective virus to effective vector. Virology Journal, 2005, 2, 43. | 1.4 | 184 |
| 53 | Stable transduction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors. Virology, 2004, 321, 287-296. | 1.1 | 23 |
| 54 | Efficient Generation and Amplification of High-Capacity Adeno-Associated Virus/Adenovirus Hybrid Vectors. Journal of Virology, 2002, 76, 10734-10744. | 1.5 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Generation of a High-Capacity Hybrid Vector: Packaging of Recombinant Adenoassociated Virus Replicative Intermediates in Adenovirus Capsids Overcomes the Limited Cloning Capacity of Adenoassociated Virus Vectors. Virology, 2001, 288, 236-246. | 1.1 | 35 |